Trial Profile
Open-label, single-arm, multicenter, investigators initiated phase II clinical trial to evaluate the efficacy and safety of IDEC-C2B8 in patients with steroid treatment-resistant pemphigus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Dec 2019
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Pemphigus
- Focus Therapeutic Use
- 23 Dec 2019 Status changed from active, no longer recruiting to completed.
- 18 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Oct 2016 New trial record